Medpace Holdings, INC Form 4 insider transactions

Medpace Holdings, Inc. Director Brian T. Carley was granted 143 restricted stock units, vesting over four installments through December 2026.

Medpace Holdings CEO August J. Troendle reported direct sales of 56,482 shares of common stock totaling approximately $34.09 million in late November 2025.

Medpace Holdings, Inc. CEO August J. Troendle sold 101,417 shares of common stock for approximately $61.9 million in pre-arranged transactions.

Medpace Holdings' Executive VP of Operations, Susan E. Burwig, filed a Form 4 indicating a planned sale of 20,000 shares of common stock on November 24, 2025, for an average price of $609.15, executed under a Rule 10b5-1 plan.

Medpace Holdings, Inc. CFO Kevin M. Brady exercised stock options and subsequently sold a portion of the acquired shares, while also gifting a small number of shares.

Medpace Holdings CEO August J. Troendle sold 28,688 shares of common stock for approximately $17 million through a pre-arranged trading plan.

Medpace Holdings CEO August J. Troendle sold over 31,000 shares of common stock in mid-November 2025 through a pre-arranged 10b5-1 plan.

Director Robert O. Kraft exercised options at $54.99 and sold 6,472 shares at a $591.85 weighted average on November 14, 2025, leaving 833 shares owned.

CEO August J. Troendle sold 20,794 Medpace shares at weighted averages of $595.26 and $591 within price ranges of $590.00–$600.51 and $590.00–$593.185, and now holds 893,368 direct shares plus 4,733,019 indirectly.

Medpace Holdings CEO August J. Troendle reported the sale of 10,440 shares of common stock over two days in November 2025.

A Medpace Holdings, Inc. executive sold 18,000 shares of common stock for $605 per share on November 11, 2025, as part of a pre-arranged plan.

Medpace Holdings, Inc. President Jesse J. Geiger sold 21,503 shares of common stock at a weighted average price of $595.66 per share under a pre-arranged 10b5-1 plan.

Medpace Holdings Director Fred B. Davenport Jr. exercised stock options and subsequently sold a portion of his common stock holdings.

Medpace Holdings, Inc. President Jesse J. Geiger sold a total of 23,028 shares of common stock after exercising employee stock options.

Medpace Holdings' General Counsel, Stephen P. Ewald, exercised stock options and subsequently sold a portion of the acquired common stock.

Medpace Holdings, Inc. Executive Vice President of Operations, Susan E. Burwig, reported the sale of 2,000 shares of common stock for approximately $1.21 million.

Medpace Holdings, Inc. Director Robert O. Kraft converted 57 restricted stock units into common stock and disposed of 833 common shares on September 30, 2025.

Medpace Holdings Director Cornelius P. McCarthy III converted 49 restricted stock units into common stock on September 30, 2025, increasing his direct beneficial ownership to 10,246 shares.

Medpace Holdings, Inc. Director Brian T. Carley acquired 62 shares of common stock through the vesting of restricted stock units.

Medpace Holdings, Inc. Executive VP, Operations, Susan E. Burwig, exercised 10,000 employee stock options at $107.93 per share.

Medpace Holdings, Inc. Executive Vice President of Operations, Susan E. Burwig, sold 10,000 shares of common stock for approximately $4.8 million.

Medpace Holdings CEO August J. Troendle sold over 37,000 shares of common stock in pre-scheduled transactions under a 10b5-1 plan.

Medpace Holdings, Inc. CEO August J. Troendle sold 620 shares of common stock at $475 per share, executed under a pre-arranged trading plan.

Medpace Holdings, Inc. Executive Vice President of Operations, Susan E. Burwig, filed a Form 4 indicating a planned exercise of 10,000 stock options in August 2025.

A director at Medpace Holdings, Inc. reported the sale of 1,662 shares of common stock for approximately $465.04 per share.

Medpace Holdings, Inc.'s General Counsel, Stephen P. Ewald, reported a sale of 3,000 common shares and committed to disgorge profits due to a Section 16(b) short-swing trading violation.

Medpace Holdings, Inc. Executive Vice President of Operations, Susan E. Burwig, reported a pre-planned sale of 7,500 shares of common stock scheduled for July 28, 2025, at a weighted average price of $450.14 per share.

Medpace Holdings CEO and 10% owner, August J. Troendle, sold 48,487 shares of common stock for approximately $21.9 million in a pre-arranged transaction.

Medpace Holdings, Inc. President Jesse J. Geiger exercised stock options and subsequently sold a portion of the acquired common stock on July 24, 2025, as part of a pre-planned trading arrangement.

Medpace Holdings, Inc. CFO & Treasurer Kevin M. Brady exercised stock options and subsequently sold a portion of the acquired shares.